US Denies Coherus’ Petitions Challenging AbbVie’s Patent for Humira

September 15, 2017: By Jon Swedien

legal issuesThe US Patent Trial and Appeal Board has denied Coherus BioSciences’ four petitions seeking invalidation of a Humira patent held by Chicago-based AbbVie, Coherus announced Sept. 7.

Humira (adalimumab) posted sales of $16 billion in 2016, accounting for most of AbbVie’s revenues.

The anti-inflammatory drug is used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and several other diseases and medical conditions.

In June 2016, the FDA approved Humira as a treatment for noninfectious intermediate and posterior uveitis and panuveitis.

The drug is protected by several patents that run through 2022.

Coherus prevailed in May in a petition against a different Humira patent.

The Redwood City, California, company has created a biosimilar version of Humira, CHS-1420.

Coherus planned to file for US approval of its biosimilar in the first half of 2018.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Offers Compounded Alternative to Restasis for Dry Eye

US District Court Invalidates Four Restasis Patents

BioTime Prices $25 Million Public Offering of Common Stock

Gemini Completes $42.5 Million Series A Financing for Dry AMD Treatment

BIOPHYTIS Raises €10.4 Million to Develop Anti-Aging Drugs, One for Dry AMD

Amydis Receives $530 Thousand NIH Award to Advance Ophthalmic Diagnostic Probes

Realm Announces Completion of $26 million Private Placement

Sight Sciences Secures $10 Million in Oversubscribed Series C Financing

Aerpio Names Stephen Hoffman CEO; Founder Joseph Gardner Remains President

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022